Early Surfactant Guided by Lamellar Body Counts on Gastric Aspirate in Very Preterm InfantsVerder H.a · Ebbesen F.e · Fenger-Grøn J.g · Henriksen T.B.f · Andreasson B.j · Bender L.e · Bertelsen A.a · Björklund L.J.k · Dahl M.h · Esberg G.f · Eschen C.a · Høvring M.a · Kreft A.i · Kroner J.h · Lundberg F.j · Pedersen P.c · Reinholdt J.b · Stanchev H.d
aDepartment of Pediatrics, Holbæk Hospital, Holbæk, bDepartment of Neonatology, Rigshospitalet, Copenhagen, cDepartment of Pediatrics, Hvidovre Hospital, Hvidovre, dDepartment of Pediatrics, University of Copenhagen, Næstved, eDepartment of Pediatrics, Aalborg Hospital, Aalborg, fDepartment of Pediatrics, Aarhus University Hospital, Skejby, gDepartment of Pediatrics, Kolding Hospital, Aarhus University, Aarhus, hDepartment of Pediatrics, Odense Hospital, Odense, and iDepartment of Pediatrics, Sønderborg Hospital, University of South Denmark, Sønderborg, Denmark, and jDepartment of Neonatology, Malmö, and kDepartment of Neonatology, Skåne University Hospital, University of Lund, Lund, Sweden
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
Background: We have developed a rapid method, based on lamellar body counts (LBC) on gastric aspirate, for identifying newborns who will develop respiratory distress syndrome with a need for surfactant supplementation. Objective: We set out to test whether it was possible to improve the outcome when used in a clinical trial. Methods: We randomly assigned 380 infants born at 24-29 weeks' gestation and supported with nasal continuous positive airway pressure (nCPAP) to receive surfactant guided either by LBC (intervention group) or increasing need for oxygen (control group). The primary outcome was mechanical ventilation or death within 5 days. Secondary outcomes included need for oxygen expressed by arterial to alveolar oxygen tension ratio (a/APO2) at the age of 6 h and need for oxygen at day 28. Results: The primary outcomes were equal (25%) in the two groups. The intervention group had higher a/APO2 than the control group at 6 h, median 0.64 versus 0.52 (p < 0.01), and the subgroup with gestational age 26-29 weeks needed fewer days of oxygen supplementation than the controls, median 2 vs. 9 days (p = 0.01), and fewer infants needed oxygen at day 28 (p = 0.04). Furthermore, there was a tendency in the intervention group towards a shorter duration of nCPAP. Too little or viscose aspirate in 23% of the cases was a limitation of the method. Conclusion: Using LBC test as indicator of lung maturity and early surfactant therapy in very preterm newborns, it is possible to reduce the need for oxygen supplementation.
© 2013 S. Karger AG, Basel
- Kamper J, Wulff K, Larsen C, Lindequist S: Early treatment of airway pressure in very low-birth-weight infants. Acta Paediatr 1993;82:193-197.
- Polin RA, Sahni R: Newer experience with CPAP. Semin Neonatol 2002;7:739-789.
- Verder H: Nasal CPAP has become an indispensable part of the primary treatment of newborns with respiratory distress syndrome. Acta Paediatr 2007;96:482-484.
- Verder H, Albertsen P, Ebbesen F, Greisen G, Robertson B, Bertelsen A, Agertoft L, Djernes B, Nathan E, Reinholdt J: Nasal continuous positive airway pressure and early surfactant therapy for respiratory distress syndrome in newborns less than 30 weeks' gestation. Pediatrics 1999;103:e24.
- Sandri F, Plavka R, Ancora G, Simeoni U, Stranak Z, Martinelli S, Mosca F, Nona J, Thomson M, Verder H, Fabbri L, Halliday H: Prophylactic or early surfactant combined with nCPAP in very preterm infants. Pediatrics 2010;125:e140.
- Bevilacqua G, Parmagiani S, Robertson B: Prophylaxis of respiratory distress syndrome by treatment with modified porcine surfactant at birth: multicentre prospective randomized trial. J Perinat Med 1996;24:1-12.
- Soll RF: Early versus delayed selective surfactant treatment for neonatal respiratory distress syndrome. Cochrane Database Syst Rev 1999;4:CD001456.
- Stevens TP, Blennow M, Meyers EH, Soll R: Early surfactant administration with brief ventilation vs. selective surfactant and continued respiratory mechanical ventilation for preterm infants with or at risk for respiratory distress syndrome. Cochrane Database Syst Rev 2007;4:CD003063.
- Verder H, Robertson B, Greisen G, Ebbesen F, Albertsen P, Lundstrøm K, Jacobsen T: Surfactant therapy and nasal continuous positive airway pressure for newborns with respiratory distress syndrome. N Engl J Med 1994;331:1051-1055.
- Soll RF: Prophylactic versus selective use of surfactant in preventing morbidity and mortality in preterm infants. Cochrane Review Update. Neonatology 2012;102:169-171.
- Castillo A, Sola A, Baquero H, Neira F, Alvis R, Deulofeut R, Critz A: Pulse oxygen saturation levels and arterial oxygen tension values in newborns receiving oxygen therapy in the neonatal intensive care unit: Is 85% to 93% an acceptable range? Pediatrics 2008;121:882-889.
- Gilbert R, Keighly JF: The arterial-alveolar oxygen tension ratio: an index of gas exchange applicable to varying inspired oxygen tension concentrations. Am Rev Respir Dis 1974;109:142-145.
- Hall RT: Indications for surfactant therapy - the aAPO2 coming of age. Pediatrics 1999;103:e25.
- Van Kaam AH, Jaegere AP, Borensztajn D, Rimensberger PC; Neovent Study Group: Surfactant replacement therapy in preterm infants: a European survey. Neonatology 2011;100:71-77.
- Dubin SB: Characterization of amniotic fluid lamellar bodies by resistive-pulse counting: relationship to measures of fetal lung maturity. Clin Chem 1989;35:612-616.
- Verder H, Ebbesen F, Brandt J, Dahl M, Esberg G, Eschen C, Grytter C, Kroner J, Nørgaard M, Reinholdt J, Stanchev H: Lamellar body counts on gastric aspirates for prediction of respiratory distress syndrome. Acta Paediatr 2011;100:175-180.
- Benveniste D, Berg O, Pedersen JE: A new technique for delivery of continuous positive airway pressure to the neonate. J Pediatr 1976;88:1015-1019.
- Moa G, Nilsson K, Zetterström H, Jonsson LO: A new device for administration of nasal continuous positive airway pressure in the newborn: an experimental study. Crit Care Med 1988;16:1238-1242.
- Halliday HL, Tarnow-Mordi WO, Cocoran JD, Patterson CC: Multicentre randomised trial comparing high and low dosis surfactant regimens for the treatment of respiratory distress syndrome (the Curosurf trial). Ach Dis Child 1993;9:276-280.
- Papile LA, Burstein J, Burstein R, Koffler H: Incidence and evolution of subependymal and intraventricular haemorrhage: a study of infants with birth weight less than 1,500 g. J Pediatr 1978;92:529-534.
- Hill A, Melson GL, Clark HB, Volpe JJ: Hemorrhagic periventricular leucomalacia: diagnosis by real time ultrasound and correlation with autopsy findings. Pediatrics 1982;69:282-284.
Altman DG: Practical Statistics for Medical Research. London, Chapman & Hall, 1991.
- Daniel IWBS, Fiori HH, Piva JP, Munhoz TP, Netoux A, Fiori RM: Lamellar body count and stable microbubble test on gastric aspirates from preterm infants for the diagnosis of respiratory distress syndrome. Neonatology 2010;98:150-155.
- SUPPORT Study Group of the Eunice Kennedy Shriver NICHD Neonatal Research Network. Finer NN, Carlo WA, Walsh MC, et al: Early CPAP versus surfactant in extremely preterm infants. N Engl J Med 2010;362:1970-1979.
- Morley CJ, Davis PG, Doyle LW, Brion LP, Hascoet JM, Carlin JB; Coin Trial Investigators: Nasal CPAP or intubation at birth for very preterm infants. N Engl J Med 2008;358:700-708.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.